• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DGL
Click for more information
0.00% 46.5¢

DGL GROUP LIMITED - Charts / Financials

Market Cap $132.6M  ! watchlist Created with Sketch. Add to my watchlist
Chemicals Chemicals Specialty Chemicals

DGL Group Limited is a diversified industrial company offering a full-service solution... DGL Group Limited is a diversified industrial company offering a full-service solution from manufacturing to recycling. The Company’s segments include Environmental solutions, Chemical manufacturing, Logistics, and Corporate. The Environmental solutions segment is focused on resource recovery and waste management. Its core activities comprise liquid waste treatment, end-of-life lead acid battery (ULAB) recycling and lead smelting and refining. The Chemical Manufacturing segment produces its own range of specialty chemicals and undertaken advanced formulation and contract manufacturing on behalf of third parties. Its operations are focused on deriving chemicals from complex reactions in controlled environments. The Logistics segment offers transport, logistics and warehousing services focusing on dangerous and hazardous goods across Australia and New Zealand. The segment also manages logistics and distribution for other goods including food, and pharmaceutical products.More

refresh Created with Sketch. REFRESH
Last update - 12.20pm 02/10/2024 (20 minute delay) ?
Day
Open 46.5¢   Day High 46.5¢   Day Low 46.5¢
Daily Volume 4083
Bids   Sellers
Number Price Volume   Number Price Volume
1 46.0¢ 150   3 46.5¢ 40704

Data source: Refinitiv

(20min delay)
Last
46.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $132.6M
Open High Low Value Volume
46.5¢ 46.5¢ 46.5¢ $1.899K 4.083K

Buyers (Bids)

No. Vol. Price($)
1 150 46.0¢
 

Sellers (Offers)

Price($) Vol. No.
46.5¢ 40704 3
View Market Depth
Last trade - 11.44am 02/10/2024 (20 minute delay) ?

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.